Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: Applying guidelines in the real world

Journal of Clinical Psychiatry

Volumn 74, Issue 10, 2013, Pages 1022-1024

  Ameis, Stephanie H ^a   Corbett Dick, Patricia ^b   Cole, Lynn ^b   Correll, Christoph U ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; RISPERIDONE;

AKATHISIA; ARTICLE; AUTISM; BEHAVIOR THERAPY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DYSKINESIA; DYSTONIA; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; HYPERACTIVITY; IMPULSE CONTROL DISORDER; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOTOR DYSFUNCTION; PARKINSONISM; PATIENT COUNSELING; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SIDE EFFECT; SOCIAL DISABILITY; STEREOTYPY; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RISK ASSESSMENT; RISPERIDONE;

EID: 84887112474     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13ac08691     Document Type: Article

References (33)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
2. Centers for Disease Control and Prevention. Prevalence of Autism Spectrum Disorders among multiple areas of the United States in 2008. Community Report From the Autism and Developmental Disabilities Monitoring (ADDM) Network, 2012. http://www.cdc.gov/ncbddd/autism/documents/ADDM-2012-Community-Report.pdf. Accessed July 18, 2013.
3. Elsabbagh M, et al Autism Res. 2012;5(3):160-179.
4. Coury DL, et al Pediatrics. 2012;130(SUPPL. 2):S69-S76.
5. De Hert M., et al Eur Psychiatry. 2011;26(3):144-158.
6. Correll CU, et al JAMA. 2009;302(16):1765-1773.
7. Lord C, et al J Autism Dev Disord. 2000;30(3):205-223.
8. Lord C, et al J Autism Dev Disord. 1994;24(5):659-685.
9. Johnson C.P., et al Pediatrics. 2007;120(5):1183-1215.
10. Myers SM, et al Pediatrics. 2007;120(5):1162-1182.
11. Siegel M, Beaulieu AA J Autism Dev Disord. 2012;42(8):1592-1605.
12. McCracken J.T., et al N Engl J Med. 2002;347(5):314-321.
13. Shea S, et al Pediatrics. 2004;114(5):e634-e641.
14. Marcus RN, et al J Am Acad Child Adolesc Psychiatry. 2009;48(11): 1110-1119.
15. Owen R, et al Pediatrics. 2009;124(6):1533-1540.
16. Anderson LT, et al Am J Psychiatry. 1984;141(10):1195-1202.
17. Campbell M, et al J Am Acad Child Adolesc Psychiatry. 1997;36(6):835-843.
18. Research Units on Pediatric Psychopharmacology Autism Network. Arch Gen Psychiatry. 2005;62(11):1266-1274.
19. King BH, et al Arch Gen Psychiatry. 2009;66(6):583-590.
20. Autism Speaks ATN. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA). 2009. www.autismspeaks.org/about-us/press- releases/autism-speaks-announces-results-reported-study-fluoxetine-autism-sofia. Accessed July 18, 2013.
21. Correll CU, et al Child Adolesc Psychiatr Clin N Am. 2006;15(1):177-206.
22. Correll CU. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20.
23. Findling R, Drury S, Jensen P., et al.; AACAP Committee on Quality Issues. Practice parameters for the use of atypical antipsychotic medications in children and adolescents 2011. http://www.aacap.org/App-Themes/AACAP/docs/ practice-parameters/Atypical-Antipsychotic-Medications-Web.pdf. Accessed July 18, 2013.
24. Panagiotopoulos C, et al J Can Acad Child Adolesc Psychiatry. 2010;19(2):124-137.
25. Pringsheim T, et al Paediatr Child Health (Oxford). 2011;16(9):581-589.
26. National Institute of Mental Health. Psychopharmacol Bull. 1985;21:1077-1080.
27. Simpson GM, Angus J W. Acta Psychiatr Scand suppl. 1970;212(S212):11-19.
28. Scotto Rosato N., et al Pediatrics. 2012;129(6):e1577-e1586.
29. De Hert M., et al Nat Rev Endocrinol. 2012;8(2):114-126.
30. Autism Speaks ATN. Tool kits. http://www.autismspeaks.org/family- services/tool-kits.
31. Knapp P, et al Pediatrics. 2012;129(6):e1562-e1576.
32. Stacey D, et al Med Decis Making. 2012;32(3):E22-E33.
33. US Dept Health and Human Services, Substance Abuse and Mental Health Services Administration. Shared decision making in mental health. http://store.samhsa.gov/shin/content/SMA09-4371/SMA09-4371.pdf